Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat

By Kamal Choudhury Oct 22 (Reuters) – Moderna's shares sank over 25% on Thursday as late-stage trial data for its personalized melanoma vaccine, developed with Merck, triggered what analysts called a

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)